Biomet Complainants Move to Centralize M2a Magnum Lawsuits

Biomet’s M2a Magnum hip replacement has been included in the Food and Drug Administration’s (FDA) watch list because of the disturbing number of reported complaints from patients and hundreds of Biomet lawsuits filed in the United States, an online source reveals.  A consolidation of M2a Magnum lawsuits took place on October 4, 2012 by the judicial panel of multidistrict litigation headed by Judge Robert Miller, says a report published in dockets.justia.com/docket/indiana/inndce/3:2012md02391/71286/. M2a Magnum is a metal-on-metal hip replacement by Biomet Orthopedics. It used to be the company’s in-demand medical device among its line of products but has recently been receiving negative feedbacks from patients who claimed that its design was defective, causing metal toxicity and early failure.

Originally, Biomet disagreed that an MDL was needed, arguing that the M2a Magnum failure rate is not as high compared with other metal-on-metal hip replacements from other manufacturers. Furthermore, the subject of these lawsuits was never recalled unlike what happened to DePuy’s ASR XL, which was subjected to a pullback in 2010.

The judicial panel, however, declined Biomet’s motion, explaining that although Biomet has settled lawsuits in the past, there were 308 cases that were already included in the MDL and most of them are opting for litigation in court. These patients have even contacted a Biomet lawyer to represent them in court.

For more information, please visit: Plaintiffs Who Moved to Centralize Biomet M2a Magnum Hip Lawsuits From California